Compare Hims and Hers Health Inc (HIMS) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Meta Platforms Inc — how do they compare? Hims and Hers Health Inc trades at $30.7 (market cap $7.35B), while Meta Platforms Inc trades at $601.89 (market cap $1.52T). The key difference: Meta Platforms Inc is far larger — about 206.8× Hims and Hers Health Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | META | |
|---|---|---|
Market Cap | $7.35B | $1.52T |
Sector | Health | Media |
52-Week High | $62.76 | $790.00 |
52-Week Low | $14.52 | $525.72 |
Enterprise Value | $7.73B | $1.54T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.
The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.
META trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed. Technical indicators show bearish momentum with RSI at 96.23 suggesting overbought conditions. The company launched Muse Spark AI model and faces ongoing legal challenges regarding youth addiction lawsuits.
Outlook remains positive with analyst consensus price target of $761.95 (28% upside) and 79% buy ratings. Key risks include regulatory lawsuits, aggressive AI capex spending ($102B in 2025), and competitive pressures. Revenue growth continues at 22% year-over-year to $201B, supporting long-term investment thesis despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
